Vosoritide

Vosoritide — ADMETatlas

Computed descriptors

Core descriptors39 aa · pI 10.6 · GRAVY -0.77

Length: 39 aa
Monoisotopic mass: 4102.11 Da
Average mass: 4104.78 Da
Net charge at pH 7.4: 6.10
Estimated pI: 10.58
GRAVY: -0.774
KD-positive residues: 28.2%
Aromatic residues: 5.1%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophilic
Amphipathic moment (μH): 0.06
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

9.96

pH 5

7.19

pH 6

6.78

pH 7.4

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

22-28

GCFGLKL

GRAVY 1.171

Most hydrophilic window

4-10

EHPNARK

GRAVY -2.629

33 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Oxidation-sensitive residues

M, C · pos 23, 34, 39

Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.

Cys covalent complexity

C · pos 23, 39

Multiple cysteines can indicate disulfide or free-thiol interpretation requirements.

Pro/Gly-rich sequence

P/G · pos 1, 2, 6, 13, 18, 22 +4

High Pro/Gly content can affect local flexibility and secondary-structure propensity.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 0.06100°/residue · 39 aa

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

5. Exposure / Absorption

What evidence describes systemic exposure or absorption?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Tmax Cmax AUC Bioavailability

Bioavailability, AUC, Cmax, and Tmax evidence.

Evidence interpretation

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Bioavailability1 measurement · 0 comparable · 1 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	Observation Absolute bioavailability for vosoritide following subcutaneous injection was not determined.	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Vosoritide· 12.3 Pharmacokinetics · bioavailability not determined text · Absolute bioava...	Open

AUC

Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.

6. Distribution / Barrier

What is known about distribution, binding, permeability, or barrier crossing?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Plasma protein binding Vd

Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	2880-3020 mL/kg	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Vosoritide· 12.3 Pharmacokinetics · volume of distribution mean sd range · Distribution T...	Open

Plasma protein binding

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.

7. Metabolic & Proteolytic Stability

How stable is the peptide in biological matrices or protease systems?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Serum/plasma stability

Serum/plasma stability and protease stability evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Comparable measurements

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Serum/plasma stability8 measurements · 6 comparable · 2 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	0.35 Hours 1260 seconds	Comparable	competitive radioimmunoassay · monkey · Cynomolgus monkeys plasma	Route: SC · Dose/window: 20 μg/kg per day for 26 weeks · Time: Samples from animals treated with the daily CNP-39 molecule were also obtained after the 1st and the 26th dos... · Cynomolgus monkeys plasma protease · In Vivo	Open
2	24.4 Minutes 1464 seconds	Comparable	ELISA · human · Human plasma	Route: SC · Dose/window: 15 μg/kg · Time: In a phase II study, full PK sampling was performed at days 1, 10, 29, 85 and 183, during which plasma sample... · Human plasma protease · In Vivo	Open
3	21 Minutes 1260 seconds	Comparable	ELISA · human · Human plasma	Route: SC · Dose/window: 15 μg/kg · Time: In the phase III study, full PK sampling was performed at day 1 during which plasma samples were collected pr... · Human plasma protease · In Vivo	Open
4	26.6 Minutes 1596 seconds	Comparable	ELISA · human · Human plasma	Route: SC · Dose/window: 15 μg/kg · Time: In the phase III study, full PK sampling was performed at week 26 during which plasma samples were collected... · Human plasma protease · In Vivo	Open
5	27.9 Minutes 1674 seconds	Comparable	ELISA · human · Human plasma	Route: SC · Dose/window: 15 μg/kg · Time: In the phase III study, full PK sampling was performed at week 52, during which plasma samples were collected... · Human plasma protease · In Vivo	Open
6	27 Minutes 1620 seconds	Comparable	ELISA · human · Human plasma	Route: SC · Dose/window: 30 μg/kg · Time: In a phase II study, full PK sampling was performed at days 1, 10, 29, 85 and 183, during which plasma sample... · Human plasma protease · In Vivo	Open
7	Observation N.A.	Reported	ELISA · human · Human plasma	Route: SC · Dose/window: 2.5 μg/kg · Time: In a phase II study, full PK sampling was performed at days 1, 10, 29, 85 and 183, during which plasma sample... · Human plasma protease · In Vivo	Open
8	Observation N.A.	Reported	ELISA · human · Human plasma	Route: SC · Dose/window: 7.5 μg/kg · Time: In a phase II study, full PK sampling was performed at days 1, 10, 29, 85 and 183, during which plasma sample... · Human plasma protease · In Vivo	Open

Interpretation: In vitro stability, protease stability, and percent-remaining measurements are not collapsed into one value.

8. Excretion / Persistence

What evidence describes clearance or persistence?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Clearance

Clearance and half-life evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Comparable measurements

Endpoint-ready rows with structured values and assay context.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Clearance1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	79.4-104 mL/min/kg	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Vosoritide· 12.3 Pharmacokinetics · clearance mean sd range · Elimination The mean (± SD)...	Open

Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.

Evidence landscape and measurement index

Evidence landscape

A cross-domain view of where evidence is concentrated, which interpretation layers dominate, and how traceable the measurements are.

ADMET domain

Comparable

Reported

Contextual

Exposure / Absorption

7 measurements

Distribution / Barrier

2 measurements

Metabolic & Proteolytic Stability

8 measurements

Excretion / Persistence

1 measurement

Toxicity / Safety

0 measurements

Endpoint distribution

Top evidence-bearing endpoint questions.

Serum Plasma Stability

Area Under Curve

Max Concentration

Bioavailability

Clearance

Plasma Protein Binding

Time To Max Concentration

Volume Of Distribution

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every measurement remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainLayerReferenceSpecies

#	ADMET domain	Endpoint	Reported value	Evidence layer	Assay / model	Condition	Reference
1	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	Observation N.A.	Contextual	ELISA · human · Human plasma	Route: SC · Time: In a phase II study, full PK sampling was performed at days 1, 10, 29, 85 and 183, during which plasma samples were collected predose and at 5 (± 2 min), 15 (± 2 min), 30...	Open
2	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	21 Minutes 1,260 seconds	Comparable	ELISA · human · Human plasma	Route: SC · Time: In the phase III study, full PK sampling was performed at day 1 during which plasma samples were collected predose and at 5 (± 2 min), 15 (± 2 min), 30 (± 5 min), 45 (± 5...	Open
3	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	0.35 Hours 1,260 seconds	Comparable	competitive radioimmunoassay · monkey · Cynomolgus monkeys plasma	Route: SC · Time: Samples from animals treated with the daily CNP-39 molecule were also obtained after the 1st and the 26th dose: at pre-dose, 0.08, 0.25, 0.5, 1, 2, and 4 hours postdose ·...	Open
4	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	27.9 Minutes 1,674 seconds	Comparable	ELISA · human · Human plasma	Route: SC · Time: In the phase III study, full PK sampling was performed at week 52, during which plasma samples were collected predose and at 5 (± 2 min), 15 (± 2 min), 30 (± 5 min), 45 (±...	Open
5	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	24.4 Minutes 1,464 seconds	Comparable	ELISA · human · Human plasma	Route: SC · Time: In a phase II study, full PK sampling was performed at days 1, 10, 29, 85 and 183, during which plasma samples were collected predose and at 5 (± 2 min), 15 (± 2 min), 30...	Open
6	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	26.6 Minutes 1,596 seconds	Comparable	ELISA · human · Human plasma	Route: SC · Time: In the phase III study, full PK sampling was performed at week 26 during which plasma samples were collected predose and at 5 (± 2 min), 15 (± 2 min), 30 (± 5 min), 45 (±...	Open
7	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	27 Minutes 1,620 seconds	Comparable	ELISA · human · Human plasma	Route: SC · Time: In a phase II study, full PK sampling was performed at days 1, 10, 29, 85 and 183, during which plasma samples were collected predose and at 5 (± 2 min), 15 (± 2 min), 30...	Open
8	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	Observation N.A.	Contextual	ELISA · human · Human plasma	Route: SC · Time: In a phase II study, full PK sampling was performed at days 1, 10, 29, 85 and 183, during which plasma samples were collected predose and at 5 (± 2 min), 15 (± 2 min), 30...	Open
9	Distribution / Barrier Distribution	Plasma Protein Binding	Observation plasma protein binding not determined due to hydrolysis of vosoritide in human plasma	Contextual	FDA Integrated Review Table 5 manual extraction · human · plasma	Table 5 reports the endpoint as not determined rather than a numeric binding value · retain as text evidence to explain the missing PPB value.	Open
10	Exposure / Absorption Exposure	Time To Max Concentration	15 minutes 900 seconds	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Not specified	Open

1–10 / 18

Identity & reference map

Summary4 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 4
Measurements: 18
ATL peptide ID: ATLPC0004440

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

9 / 9

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 9

Different notation

Reported notation does not resolve to the current display sequence.

0 / 9

Reference map4 of 4 shown

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
PubMed 34431071 Open	Stability Serum Plasma Stability	No reported alias PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGCexact	7 identity 7 evidence
Reference link Open	DistributionExposurePersistence Area Under Curve, Bioavailability, Clearance, Max Concentration +2 more	No reported alias	0 identity 9 evidence
PubMed 31235532 Open	Stability Serum Plasma Stability	No reported alias PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGCexact	1 identity 1 evidence
Reference link Open	Distribution Plasma Protein Binding	No reported alias PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGCexact	1 identity 1 evidence

Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.

Data access & reproducibility

Record scopePublic release

ATL peptide ID: ATLPC0004440
Identity type: canonical sequence
ADMET endpoints: 8
Measurements: 18
Reference groups: 4
Release view: Public release

Analysis-ready files

Peptide record

TSV

Identity, sequence, profile-level fields, and current release view metadata.

Download record

Programmatic access

The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.

Open endpoint

GET /api/v1/peptides/ATLPC0004440

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0004440' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.

#	Value	Evidence layer	Assay / model	Condition	Reference
1	161-290 ng*min/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Vosoritide· 12.3 Pharmacokinetics · auc mean sd range respectively · The mean (± SD) C ma...	Open
2	Observation The area under the concentration-time curve (AUC) and peak concentration (C max ) of vosoritide increased greater than proportionally following subcutaneous administration to pediatric subjects with achondroplasia in the dose range of 7.5 to 30.0 mcg/kg.	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Vosoritide· 12.3 Pharmacokinetics · cmax auc greater than dose proportionality text · The...	Open
3	Observation The mean AUC 0-t at week 52 increased approximately 20% compared to that at day 1.	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Vosoritide· 12.3 Pharmacokinetics · auc longitudinal increase text · The mean AUC 0-t at...	Open

Cmax2 measurements · 1 comparable · 1 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	4.71-7.18 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Vosoritide· 12.3 Pharmacokinetics · cmax mean sd range respectively · The mean (± SD) C m...	Open
2	Observation The area under the concentration-time curve (AUC) and peak concentration (C max ) of vosoritide increased greater than proportionally following subcutaneous administration to pediatric subjects with achondroplasia in the dose range of 7.5 to 30.0 mcg/kg.	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Vosoritide· 12.3 Pharmacokinetics · cmax auc greater than dose proportionality text · The...	Open

Tmax1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	15 minutes 900 seconds	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Vosoritide· 12.3 Pharmacokinetics · tmax of value · Vosoritide was absorbed with a median...	Open

#	Value	Evidence layer	Assay / model	Condition	Reference
1	Observation plasma protein binding not determined due to hydrolysis of vosoritide in human plasma	Reported	FDA Integrated Review Table 5 manual extraction · human · plasma	Not specified	Open

Vosoritide

Peptide developability profile

1. Sequence & peptidoform

Sequence interpretation

2. Structure & chemistry

Structure and chemistry interpretation

3. Physicochemical profile

Computed descriptors

Computed developability descriptors

4. Product context

Translational product context

5. Exposure / Absorption

Evidence summary

6. Distribution / Barrier

Evidence summary

7. Metabolic & Proteolytic Stability

Evidence summary

8. Excretion / Persistence

Evidence summary

9. Evidence landscape

Evidence landscape and measurement index

10. Identity & reference map

Identity & reference map

11. Data access & reproducibility

Data access & reproducibility

Peptide record

Evidence table

Structured record